Skip to Content
Morningstar

Canopy Growth Corp CGC

Morningstar Rating
Unlock
Stock XNAS Rating as of
$8.97 −0.06 (0.66%)
View Full Chart
As of Delayed Price Post-Trading: $8.89 −0.08
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

First Pillar of Germany's Cannabis Legalization Begins April 1; Legal Sales to Come Later

Kristoffer Inton

The Bundestag, the lower house of Germany’s legislature, passed a cannabis bill last month that would allow possession of up to 25 grams and home-growing of up to three plants. The law will become effective April 1 as planned after the Bundesrat, the upper house, voted not to send it to mediation committee on March 22. The law expands on July 1 to allow nonprofit cannabis grow clubs of up to 500 members and 50 grams per member.

Read Full Report

Price vs Fair Value

View History
CGC is trading at a 2% premium.
Price
$7.85
Fair Value
$6.40
Uncertainty
Extreme
1-Star Price
$73.40
5-Star Price
$6.21
Economic Moat
Ckby
Capital Allocation
Tfns

Bulls Say, Bears Say

Bulls

Canopy Growth’s plans to create Canopy USA to strengthen its competitive position before U.S. federal legalization.

Bears

While Canopy waits for U.S. federal legalization to enter the THC market there, U.S. multistate operators continue to grow bigger and become more competitive.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CGC is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$9.03
Day Range
$8.63–9.32
52-Week Range
$2.76–19.20
Bid/Ask
$8.89 / $8.95
Market Cap
$817.30 Mil
Volume/Avg
7.4 Mil / 12.7 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
2.31
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth is attempting to merge its U.S. assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Core
Total Number of Employees
1,621
Website
https://www.canopygrowth.com

Competitors

Valuation

View More
Metric
CGC
CURLF
TLRY
Price/Earnings (Normalized)
 ———
Price/Book Value
 1.593.460.42
Price/Sales
 2.312.661.77
Price/Cash Flow
 —62.77—
Price/Earnings
CGC
CURLF
TLRY

Financial Strength

Metric
CGC
CURLF
TLRY
Quick Ratio
 1.130.310.96
Current Ratio
 1.790.851.92
Interest Coverage
 −9.27−0.24−4.39
Quick Ratio
CGC
CURLF
TLRY

Profitability

Metric
CGC
CURLF
TLRY
Return on Assets (Normalized)
 −23.44%−3.72%−13.42%
Return on Equity (Normalized)
 −57.88%−10.45%−17.13%
Return on Invested Capital (Normalized)
 −20.86%−2.20%−14.23%
Return on Assets
CGC
CURLF
TLRY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
MKKGY
Merck KGaA ADRBbshwbgtdHchdhw$71.2 Bil
ZTS
Zoetis Inc Class ATnmstqhsnWncr$68.3 Bil
HLN
Haleon PLC ADRZxzfghzGsyq$37.5 Bil
TEVA
Teva Pharmaceutical Industries Ltd ADRWwkryhwfCdj$14.5 Bil
VTRS
Viatris IncBzpgjjlwwSnq$13.4 Bil
RDY
Dr Reddy's Laboratories Ltd ADRWkzhvhzmMzvb$11.9 Bil
CTLT
Catalent IncLhvhhlnpmYpwrgc$10.1 Bil
PRGO
Perrigo Co PLCBzpxmkmvTpcj$4.1 Bil
CURLF
Curaleaf Holdings IncHjsyttbGysx$3.6 Bil
PBH
Prestige Consumer Healthcare IncSvgpdtfYjxpnj$3.5 Bil

Sponsor Center